Stéphanie Rondeau

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

Christian Taverna, Giovanni Martinelli, Felicitas Hitz et al. · Journal of Clinical Oncology · 2015 · 63 citations

Medicine, Immunology, Pharmacotherapy +14

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Emanuele Zucca, Stéphanie Rondeau, Anna Vanazzi et al. · Blood · 2019 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08

Khalil Zaman, Christoph Mamot, Ursula Hasler-Strub et al. · European Journal of Cancer · 2015 · 51 citations

Medicine, Oncology, Pharmacology +12

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

Alden A. Moccia, Christian Taverna, Sämi Schär et al. · Blood Advances · 2020 · 24 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

Felicitas Hitz, Marianne Kraus, Thomas Pabst et al. · Blood Cancer Journal · 2019 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15